hotspot -WSS

hotspot

author：entertainment 2025-09-30 12:11:19 - browse：718

President Biden speaks on the Cancer Moonshot initiative at the John F. Kennedy Library in 2022. Evan Vucci/AP

WASHINGTON — The next chapter of President Biden’s moonshot to end cancer has landed. While the new goals are inspiring hope among cancer researchers, not everyone is impressed.

The president early Wednesday morning unveiled a slew of federal plans and private-sector agreements to fuel the relaunched Cancer Moonshot, a project to improve treatments and halve cancer deaths in the next 25 years. Among roughly 50 new programs and partnerships are multimillion-dollar pledges to advance testing, data pools, clinical trials and outreach efforts.

It is the latest phase of a project Biden first launched as vice president in the wake of his son Beau’s death from brain cancer in 2015. But while the first moonshot funneled money almost entirely to early-stage cancer research, its sequel is broadening efforts to prevent cancer deaths — particularly through anti-smoking efforts — and introduces a new focus on research infrastructure and patient engagement that some cancer researchers have applauded.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： CDC recommends rationing of RSV shot due to shortages

WSS

Ohio still needs to do more to protect the right to abortion

Eli Lilly to pay $200M for Beam’s stake in gene

Diversifying clinical trials isn't enough to close racial gaps: study

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Weight loss drugs should be covered by insurers, AMA says

hotspot

hotspot

focus

Walensky prepares to leave CDC — and Congress — behind

The FDA weighs the risks of candy

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Novavax promises a turnaround & Lilly roils the obesity market

Paying for Covid pills will soon shift to insurers

Medicare details structure of new drug price negotiation program

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

focus

Why Sanofi got shellacked over its spinoff

Senate panel to vote on hospitals, PBMs, prisoner care

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Telehealth options flood the market as retailers push virtual care

Healthy food access boosts outcomes in two studies

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

focus

Wikipedia

leisure time

leisure time